The company's missed forecasts and lack of positive strategic review results may dampen investor sentiment. However, cost savings from discontinuing early-stage drugs and reducing staff, along with share buybacks, could offset some negativity.
Recent insider selling activity and lack of trades in the last quarter at Aurinia Pharmaceuticals may concern investors. However, modest insider ownership could suggest alignment between management and smaller shareholders.
Shareholders may not be comfortable amid potentially dimmer future expectations for the company, possibly causing the lower P/S ratio. A shift in the company's fortunes would be required to justify an increase in the P/S.
High confidence in Aurinia Pharmaceuticals with anticipated average yearly growth rate of 71%. A slower rate will delay profitability. Company's debt-free status lowers investment risk.
If the company can sustain its revenue growth, the share price may further increase. The company's performance appears to have improved recently, as the one-year total shareholder return is better than the five-year total shareholder return.
Analysts predict Aurinia Pharmaceuticals will breakeven before running out of cash. Its growth trajectory and ability to raise funds mitigates the risk of cash burn.
$オーリニア・ファーマシューティカルズ(AUPH.US)$Looks ready to head back towards the top of its trading channel. I'm still holding long shares waiting on the buyout and now playing calls trying to get some more free shares 🏹🚀
オーリニア・ファーマシューティカルズに関するコメント
Top tenbagger predictions in Sept 2019 and where they are now
210 upvotes: $イテリス(ITI.US)$ $6.21 then. $4.37 now. (-30%)
42 upvotes: $エンフェーズ・エナジー(ENPH.US)$ $27.47 then. $117.57 now. (328%)
23 upvotes: $Livent(LTHM.US)$ $7.28 then. $20.14 now. (177%)
14 upvotes: $EROS RESOURCES CORP(EROSF.US)$ $18.70 then. $18.95 now. (1.34%)
10 upvotes: $ウーバー・テクノロジーズ(UBER.US)$ $32.60 then. $46.60 now. (43%)
7 upvotes. $オーリニア・ファーマシューティカルズ(AUPH.US)$ $6.06 then. $8.4...
Nailed it
まだコメントはありません